Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
The purpose of this study is to test if visualizing the heart with cardiac MRI/echo will be important in the understanding cardiac function and prediction of cardiopulmonary symptoms, physical effort tolerance, and outcomes in COVID-19 survivors. If successful, the research will allow us to identify the causes of lasting cardiopulmonary symptoms and begin developing cardiac and lung directed therapies accordingly.
Conditions:
🦠 COVID-19 Pneumonia 🦠 COVID-19 🦠 COVID-19 Respiratory Infection 🦠 COVID-19 Acute Respiratory Distress Syndrome 🦠 COVID-19 Lower Respiratory Infection 🦠 COVID-19 Acute Bronchitis 🦠 Coronavirus Disease 2019
🗓️ Study Start (Actual) 1 July 2021
🗓️ Primary Completion (Estimated) 30 July 2026
✅ Study Completion (Estimated) 30 July 2026
👥 Enrollment (Estimated) 510
🔬 Study Type OBSERVATIONAL
📊 Phase N/A
Locations:
📍 Brooklyn, New York, United States
📍 New York, New York, United States
📍 New York, New York, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * Emergency room presentation and/or hospitalization with COVID-19 infection defined in accordance with established criteria as follows: SAR-CoV2 RT-PCR+ (severe acute respiratory syndrome coronavirus 2 reverse transcription polymerase chain reaction) and at least one of the following symptoms: dyspnea, cough, dysphagia, rhinorrhea, diarrhea, nausea/vomiting, myalgias, fever, syncope/presyncope.

    Exclusion Criteria:

    • * Contraindication to CMR (i.e. non-compatible pacemaker/defibrillator) or gadolinium (known hypersensitivity, eGFR (estimated globular filtration rate) \<30 ml/min/1.73m2).
    • * Inability to provide informed consent (e.g. cognitive impairment).
    • * Unrelated condition (e.g. neoplasm) with life expectancy \<12 months prohibiting follow-up.
    • * Patients with contraindications to gadolinium (known or suspected hypersensitivity, glomerular filtration rate \< 30 ml/min/1.73m2) will undergo non-contrast MRI but will not be excluded from this study.
    • * Patients with known or suspected pregnancy based on Weill Cornell Radiology intake surveys (reviewed by a clinical RN (registered nurse), as well as research personnel) will be excluded from the protocol.
Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 20 December 2021
  • First Submitted that Met QC Criteria 20 December 2021
  • First Posted 21 December 2021

Study Record Updates

  • Last Update Submitted that Met QC Criteria 20 March 2024
  • Last Update Posted 22 March 2024
  • Last Verified March 2024